Loading
Use tumour DNA in the blood as the signal to pause and restart a lung cancer pill, keeping the tumour in check while slowing the rise of resistant cells.
Adaptive therapy needs a fast, quantitative burden marker. In EGFR- and ALK-driven lung cancer, ctDNA falls to undetectable within weeks of TKI and rises before scans show progression. The proposal is a rules-based algorithm: pause the TKI when ctDNA has been undetectable for two consecutive draws, restart at reappearance, and compare with continuous dosing.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
One of the most cited trial reports Europe PMC returns for EGFR in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for EGFR in Non-small-cell lung cancer, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Tumour heterogeneity and clonal evolution.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Wrong doses.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Osimertinib.
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Circulating tumour DNA (ctDNA).
Shares Tumour heterogeneity and clonal evolution, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Osimertinib, Acquired resistance to every therapy.
Shares Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, EGFR-mutated non-small-cell lung cancer.
Shares Tumour heterogeneity and clonal evolution, Osimertinib, Acquired resistance to every therapy, Liquid biopsy (ctDNA).
Shares FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer, Wrong doses, Osimertinib, Acquired resistance to every therapy.